Targeting Triple-negative Breast Cancer
The FDA has approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic...
The FDA has approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic...
The FDA approval is for the use of atezolizumab in combination with Abraxane for the treatment of certain patients...
The U.S. Food and Drug Administration approval provides a new option for patients with liposarcoma and leiomyosarcoma that is...
Cancer immunotherapy is making headlines and generating excitement among biomedical researchers, clinicians, patients and their families, and research advocates....
The former president, who announced in August 2015 he had metastatic melanoma, recently said he was cancer-free after treatment...
The FDA has approved the ALK inhibitor alectinib for surgically resectable NSCLC. The U.S. Food and Drug Administration (FDA)...
The FDA has approved the FGFR inhibitor erdafitinib for certain patients with urothelial carcinoma The U.S. Food and Drug...
The U.S. FDA approved the combination of lenvatinib and pembrolizumab to treat adult patients with renal cell carcinoma, the...
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with...
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a...
Progression-free survival among certain patients with metastatic colorectal cancer continued at a high level after immune checkpoint inhibitor therapy...
Enfortumab vedotin-ejfv plus pembrolizumab was approved for certain bladder cancers. The U.S. Food and Drug Administration (FDA) has approved...
The FDA approved a combination of an immunotherapy and a therapeutic that can stop tumors from growing blood vessels...
The U.S. Food and Drug Administration approval of niraparib means there are now three PARP inhibitors that can be...
Patients with lung cancer who received an immune checkpoint inhibitor before surgery had improved long-term survival rates and lower...
The FDA approved the cellular immunotherapy axicabtagene ciloleucel for second-line treatment of patients with large B-cell lymphoma. The U.S....
The FDA has granted full approval to an antibody-drug conjugate for certain patients with breast cancer. The U.S. Food...
The CAR T-cell therapy lisocabtagene maraleucel was approved for the second-line treatment of certain patients with large B-cell lymphoma. ...
First-line nivolumab with chemotherapy was approved for bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab...
The FDA has approved a new molecularly targeted therapeutic to treat breast cancer patients with a specific subtype of...
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients...
The FDA has expanded the use of a CD30-targeted antibody?drug conjugate to include two additional types of lymphoma. The...
The FDA has approved the combination of ibrutinib and rituximab as a new treatment for a rare form of...
Non-invasive scanning for biomarkers after only 1 week may guide treatment for some patients with melanoma and avoid surgery...
New findings may help physicians monitor for adverse reactions to immunotherapy and allow for early intervention. A potentially severe...
Underrepresentation of members of minority groups in public genomic databases could lead to misleading test results, and more news...
The FDA has approved an alternative dosing schedule for the immune checkpoint inhibitor pembrolizumab. On April 28, 2020, the...
Legislation to speed cancer drug development for children and adolescents requires drug companies to test drugs in children, but...
A urine test may help grade prostate cancers without biopsies, and states look for savings and better health in...
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form...